Micro-cap biotech company has "destructively innovative technology" and great management.
Most microcap investors have one goal in common: they want to hit a home run. They all want to be among the early investors to find an undervalued, publicly traded company that has the obvious potential to return 10, 50, even 100 times the original investment. Moreover, this proverbial investor would like the feeling of buying close to a near-term bottom and would like to feel so certain of the company’s intermediate and long-term merits that any dips would just be proverbial buying opportunities. What are some of the characteristics that one might look for in the hunt for the next Genentech (NYSE: DNA, Stock Forum), Microsoft (NASDAQ: MSFT, Stock Forum), or Google (NASDAQ: GOOG, Stock Forum)? May, I suggest potential microcap investors should pay heed to two major signals that I’ve learned to trust after past successes:
1. A broadly patented, destructively innovative technology that can create a new market or enter and take over an existing consumer market, and amounts to multi-billion dollar annual revenue potential.
2. A sage and sound management team that surrounds the technology and who intimately understands the history and development of the technology. These same persons can also attract licensing partners and investors who can collaborate and fund the technology through the stages of development necessary for the creation of novel commercial products that are superior to the existing competition at the same or lower price.
One public company that has many and might soon have all of the above characteristics is Nanoviricides (OTC:BB: NNVC, Stock Forum). It was featuredon Stockhouse last April. However, that article’s scope was rather focused upon the companies’ outstanding preclinical results in animal and cell culture studies in three categories of anti-viral disease, viz. HIV, Herpes and variants of Influenza. This alone was enough, but investors need a little more challenge to investigate the company’s website, , and use their scientifically informed imagination to form a vision of this microcap’s economic potential. I believe that when such is done that one can possibly put together a scenario for both Nanoviricides’ Theracour© technology that might rival the commercial success of other pharmaceuticals and biotechnology shares that have become the famous Peter Lynch 10 baggers, twice over.
Nanoviricides has the global licensing and marketing rights to the Theracour© technology developed and broadly patented by Dr. Anil Diwan. As the original scientist and inventor, Dr. Diwan, serving as President of Nanoviricides, assures the shareholder family that he possesses the experience, expertise, and knowledge to bring this nanobiotechnology from its past and current successes with cell culture and animal testing into FDA clinical trials. Importantly, such managerial depth can protect a company from underselling its technology or having it stolen by stronger, hostile entities. Also, it should be studied—and as noted on the company’s website—that its long, horizontal development has provided 9 separate potential nano-drug candidates, four of which represent a whopping 40 billion dollar annual market, according to CEO Eugene Seymour in an October 26, 2009 company announcement. These four nanopharma compounds address HIV, all influenzas, viral diseases of the external eye, and herpes simplex infections, including cold sores and genital herpes. Dr. Seymour also announced the company’s recent equity raise of 4.3 million dollars in equity at 57 cents a share was enough money to take the company comfortably through 2010; investors should also note that the previously mentioned offering had warrants attached, exercisable at a $1.00 share.. Off balance sheet, Dr. Seymour estimates that the United States government and its various agencies have invested what could be worth 10 to 15 million dollars testing Nanoviricides’ Theracour© technology. These factors should be considered by those who see the company’s low book value per share as well as its approximate 132 million outstanding shares.
The Nanoviricides Theracour© technology is to my research a singularly unique antiviral technology. The destructively innovative nanomaterials are specifically designed like smart-guided missiles to specifically attack the viral envelope, dismantle and destroy them. Simple yet profound and the company’s CEO, Dr. Eugene Seymour MD, believes that the nanobiotechnology could have therapeutic application in as many as 95% of all viruses known to humankind.
When cerebrating on the cosmos and the complexities of its physical laws, Einstein famously let loose his imagination in thought experiments designed to betray the hidden workings of the universe. He often asked himself the question, "How would God create the world"? Its becoming obvious that Anil Diwan, the President and inventor of the Nanoviricides Theracour Technology has had an Einsteinian eclipse within the realm of antiviral nano-technology. At a Harvard Beth Israel preclinical trial that tested the therapeutic efficacy of Nanoviricides against HIV one of the researchers exclaimed "We have found the Holy Grail", after the astounding animal results were concluded.
According to my research less than 30 million shares are in the public float. Technically the shares have exhibited strong upward volume over last two weeks. I believe that this will continue for sometime in the future with brief interludes of profit taking.
Disclosure: My family members and I currently own less than 5,000 shares.
For further information go to www.nanoviricides.com, for questions contact NNVC, CEO Eugene Seymour at 310-966-1941 or eugene@nanoviricides.com
